Company intelligence / Profile preview
Zylö Therapeutics
- Ownership
- Private
- Employees
- ~7
- Development stage
- Preclinical
Overview
Zylö’s Z-pod® technology has been commercialized in the cosmetic sector (e.g., BosleyMD Revive+ Densifying Foam) with peer-reviewed evidence supporting superior sustained topical delivery. In pharma applications—now spun out into Atticus Pharma—the technology targets alopecia and wound healing with exclusive rights to YuvaBio’s Y200 extract. Clinical results are early-stage or preclinical at this time
- Therapeutic areas
- Dermatology
- Modalities
- Sustained-release topical delivery using silica-derived particles ("Z-pods"); can encapsulate a range of agents including small molecules and botanical extracts
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Zylö Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zylö Therapeutics.